Which patients with mild cognitive impairment do you consider referring for amyloid-targeted therapy?

This is an important question, as clearly, not everyone with MCI is appropriate or interested in Amyloid-Targeted Therapy. In general, I would say that the TRAILBLAZER-ALZ 2 trial did not change my approach to patient selection much, but it did provide more evidence that this class of drugs has a pl...

I am of the Aricept era of trials and trubulations… with these new opportunities for treatment of this debilitating disease for patients, families, and communities, I would offer some thoughts that we do not typically think about or train in, but do come to play and often cause additional agita in c...